-
Je něco špatně v tomto záznamu ?
Low Initial Adherence with Flash Glucose Monitoring is Not a Predictor of Long-Term Glycemic Outcomes: Longitudinal Analysis of the Association Between Experience, Adherence, and Glucose Control for FreeStyle Libre Users
J. Šoupal, K. Kao, L. Brandner, G. Grunberger, M. Prázný
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
RVO-VFN00064165
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
ProQuest Central
od 2010-08-01
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
Nursing & Allied Health Database (ProQuest)
od 2010-08-01
Health & Medicine (ProQuest)
od 2010-08-01
Family Health Database (ProQuest)
od 2010-08-01
Public Health Database (ProQuest)
od 2010-08-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
Springer Journals Complete - Open Access
od 2010-08-01
Springer Nature OA/Free Journals
od 2010-08-01
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: Frequent scanning of FreeStyle Libre (FSL) flash glucose monitoring sensors is known to be important whilst wearing an active sensor, but adherence to sensor reapplication is also critical to effective glucose monitoring. We report novel measures of adherence for users of the FSL system and their association with improvements in metrics of glucose control. METHODS: Anonymous data were extracted for 1600 FSL users in the Czech Republic with ≥ 36 completed sensors from October 22, 2018 to December 31, 2021. "Experience" was defined by the number of sensors used (1-36 sensors). "Adherence" was defined by time between the end of one sensor and the start of the next (gap time). User adherence was analyzed for four experience levels after initiating FLASH; Start (sensors 1-3); Early (sensors 4-6); Middle (sensors 19-21); End (sensors 34-36). Users were split into two adherence levels based on mean gap time during Start period, "low" (> 24 h, n = 723) and "high" (≤ 8 h, n = 877). RESULTS: Low-adherence users reduced their sensor gap times significantly: 38.5% applied a new sensor within 24 h during sensors 4-6, rising to 65.0% by sensors 34-36 (p < 0.001). Improved adherence was associated with increased %TIR (time in range; mean + 2.4%; p < 0.001), reduced %TAR (time above range; mean - 3.1%; p < 0.001), and reduced glucose coefficient of variation (CV; mean - 1.7%; p < 0.001). CONCLUSIONS: With experience, FSL users became more adherent in sensor reapplication, with associated increases in %TIR, and reductions in %TAR and glucose variability.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23009470
- 003
- CZ-PrNML
- 005
- 20230721095600.0
- 007
- ta
- 008
- 230707s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13300-023-01422-4 $2 doi
- 035 __
- $a (PubMed)37211580
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Šoupal, Jan $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. jan.soupal@seznam.cz
- 245 10
- $a Low Initial Adherence with Flash Glucose Monitoring is Not a Predictor of Long-Term Glycemic Outcomes: Longitudinal Analysis of the Association Between Experience, Adherence, and Glucose Control for FreeStyle Libre Users / $c J. Šoupal, K. Kao, L. Brandner, G. Grunberger, M. Prázný
- 520 9_
- $a INTRODUCTION: Frequent scanning of FreeStyle Libre (FSL) flash glucose monitoring sensors is known to be important whilst wearing an active sensor, but adherence to sensor reapplication is also critical to effective glucose monitoring. We report novel measures of adherence for users of the FSL system and their association with improvements in metrics of glucose control. METHODS: Anonymous data were extracted for 1600 FSL users in the Czech Republic with ≥ 36 completed sensors from October 22, 2018 to December 31, 2021. "Experience" was defined by the number of sensors used (1-36 sensors). "Adherence" was defined by time between the end of one sensor and the start of the next (gap time). User adherence was analyzed for four experience levels after initiating FLASH; Start (sensors 1-3); Early (sensors 4-6); Middle (sensors 19-21); End (sensors 34-36). Users were split into two adherence levels based on mean gap time during Start period, "low" (> 24 h, n = 723) and "high" (≤ 8 h, n = 877). RESULTS: Low-adherence users reduced their sensor gap times significantly: 38.5% applied a new sensor within 24 h during sensors 4-6, rising to 65.0% by sensors 34-36 (p < 0.001). Improved adherence was associated with increased %TIR (time in range; mean + 2.4%; p < 0.001), reduced %TAR (time above range; mean - 3.1%; p < 0.001), and reduced glucose coefficient of variation (CV; mean - 1.7%; p < 0.001). CONCLUSIONS: With experience, FSL users became more adherent in sensor reapplication, with associated increases in %TIR, and reductions in %TAR and glucose variability.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kao, Kalvin $u Abbott Diabetes Care, Alameda, CA, USA
- 700 1_
- $a Brandner, Laura $u Abbott Diabetes Care, Alameda, CA, USA
- 700 1_
- $a Grunberger, George $u Grunberger Diabetes Institute, Bloomfield Hills, MI, USA $u Department of Internal Medicine and Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA
- 700 1_
- $a Prázný, Martin $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00194311 $t Diabetes therapy : research, treatment and education of diabetes and related disorders $x 1869-6953 $g Roč. 14, č. 7 (2023), s. 1231-1240
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37211580 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230721095554 $b ABA008
- 999 __
- $a ok $b bmc $g 1958383 $s 1195734
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 14 $c 7 $d 1231-1240 $e 20230522 $i 1869-6953 $m Diabetes therapy $n Diabetes Ther $x MED00194311
- GRA __
- $a RVO-VFN00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20230707